MedTrace Logo

Rucaparib(CO-338;Formally Called AG-014699 or PF-0136738) in Treating Patients With Locally Advanced or Metastatic Breast Cancer or Advanced Ovarian Cancer

NCT00664781 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 78

Last updated 2016-05-24

No results posted yet for this study

Summary

RATIONALE: rucaparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

PURPOSE: This phase II trial is studying the side effects and best dose of rucaparib and to see how well it works in treating patients with locally advanced or metastatic breast cancer or advanced ovarian cancer.

Conditions

Interventions

DRUG

rucaparib (CO-338; formally AG-014699 or PF-01367338)

GENETIC

protein expression analysis

GENETIC

western blotting

OTHER

immunohistochemistry staining method

OTHER

liquid chromatography

OTHER

mass spectrometry

OTHER

pharmacological study

Sponsors & Collaborators

Principal Investigators

  • Ruth Plummer · Northern Centre for Cancer Treatment at Newcastle General Hospital

Study Design

Purpose
TREATMENT
Masking
NONE

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-12-31
Primary Completion
2015-01-31
Completion
2015-01-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00664781 on ClinicalTrials.gov